Anthera Pharma (ANTH) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Piper Jaffray Cuts Price Target on Anthera Pharma (ANTH) to $10 Following 4Q
March 11, 2016 8:31 AM ESTPiper Jaffray maintained an Overweight rating on Anthera Pharma (NASDAQ: ANTH), and cut the price target to $10.00 (from $14.00), following the company's 4Q. Anthera stopped enrollment of the Phase II BRIGHT-SC trial of blisibimod at 57 IgA Nephropathy patients, of which 45 remained on study. Also, Anthera... More
